Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo
- PMID: 11230360
- DOI: 10.1161/01.hyp.37.2.703
Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo
Abstract
In the present study, we investigated the potentiating effect of angiotensin-(1-7) [Ang-(1-7)] on bradykinin (BK)-induced vasodilation in the mesenteric vascular bed of anesthetized spontaneously hypertensive rats using intravital microscopy. Topical application of BK and Ang-(1-7) induced vasodilation in mesenteric arterioles. The BK-induced effect, but not acetylcholine, sodium nitroprusside, or histamine responses, was potentiated in the presence of Ang-(1-7). This interaction was abolished by BK-B(2) and Ang-(1-7) antagonists (HOE 140 and A-779, respectively), a K(+) channel blocker (tetraethylammonium), and cyclooxygenase inhibitors (indomethacin and diclofenac); however, nitric oxide synthase inhibition (Nomega-nitro-L-arginine methyl ester) did not modify the Ang-(1-7)-potentiating activity. Long-term angiotensin-converting enzyme (ACE) inhibition increased BK and Ang-(1-7)-induced vasodilation. The BK potentiation by Ang-(1-7) was preserved after ACE inhibition, Ang II type 1 receptor blockade, or the combination of both treatments. The most striking finding of this study was the unexpected observation that the potentiation of BK vasodilation in spontaneously hypertensive rats treated short- or long-term with ACE inhibitors was reverted by the Ang-(1-7) antagonist A-779. Our results unmasked a key role for an Ang-(1-7)-related mechanism in mediating BK potentiation by ACE inhibitors.
Similar articles
-
Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo.Peptides. 1999;20(10):1195-201. doi: 10.1016/s0196-9781(99)00123-0. Peptides. 1999. PMID: 10573291
-
Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide.Hypertension. 1997 Jan;29(1 Pt 2):394-400. doi: 10.1161/01.hyp.29.1.394. Hypertension. 1997. PMID: 9039133
-
Angiotensin-(1-7) potentiates responses to bradykinin but does not change responses to angiotensin I.Can J Physiol Pharmacol. 2006 Nov;84(11):1163-75. doi: 10.1139/y06-053. Can J Physiol Pharmacol. 2006. PMID: 17218981
-
Angiotensin-(1-7): a novel vasodilator of the coronary circulation.Biol Res. 1998;31(3):227-34. Biol Res. 1998. PMID: 9830510 Review.
-
Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin.J Mol Cell Cardiol. 2002 Dec;34(12):1569-76. doi: 10.1006/jmcc.2002.2080. J Mol Cell Cardiol. 2002. PMID: 12505055 Review.
Cited by
-
Angiotensin-(1-7): Translational Avenues in Cardiovascular Control.Am J Hypertens. 2019 Nov 15;32(12):1133-1142. doi: 10.1093/ajh/hpz146. Am J Hypertens. 2019. PMID: 31602467 Free PMC article. Review.
-
Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats.Br J Pharmacol. 2002 Apr;135(7):1743-8. doi: 10.1038/sj.bjp.0704630. Br J Pharmacol. 2002. PMID: 11934815 Free PMC article.
-
A systematic review to investigate whether Angiotensin-(1-7) is a promising therapeutic target in human heart failure.Int J Pept. 2013;2013:260346. doi: 10.1155/2013/260346. Epub 2013 Dec 12. Int J Pept. 2013. PMID: 24454410 Free PMC article. Review.
-
Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic.Biochem Pharmacol. 2023 Feb;208:115370. doi: 10.1016/j.bcp.2022.115370. Epub 2022 Dec 5. Biochem Pharmacol. 2023. PMID: 36481346 Free PMC article. Review.
-
New angiotensins.J Mol Med (Berl). 2008 Jun;86(6):663-71. doi: 10.1007/s00109-008-0340-4. Epub 2008 Apr 25. J Mol Med (Berl). 2008. PMID: 18437333 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous